Canon Medical has announced that its new Angiography system, Alphenix / Evolve Edition*¹ is now available for commercial sale in Japan, Asian, African and European markets. Utilizing deep learning technology in real-time, Alphenix / Evolve Edition is designed to enhance imaging while enabling reduced time and radiation dose during routine and complex percutaneous coronary intervention (PCI) and structural heart disease (SHD) procedures, improving safety for clinicians and patients.
Alphenix / Evolve Edition delivers a range of industry leading solutions for the Interventional Cardiology suite. Packaged under the αEvolve (alpha Evolve) technology umbrella of AI solutions, they provide real-time assistance that can instantaneously support key diagnostic and therapeutic decisions without interrupting procedural flow.
αEvolve Imaging utilizes deep learning based noise reduction and multi-frequency processing to enable sharp and clear fluoroscopic imaging, which can deliver two times higher contrast-to-noise ratio compared to conventional image processing, reducing the reliance on digital acquisition
Dynamic Device Stabilizer (DDS) has been trained with deep learning to automatically detect balloon markers in real-time, magnifying and stabilizing the image on a separate screen to assist stent visualization and assessment during complex PCI procedures.
With the rise of SHD procedures such as left atrial appendage (LAA) closure, Echo Fusion*¹*² taps into deep learning intelligence to automatically identify the echocardiography probe and efficiently fuse the fluoroscopic and echo image without additional operator input.
In addition, Alphenix / Evolve Edition offers a new level of intelligence and efficiency for the modern Interventional angiography suite through existing technologies like 12×12 inch flat panel detector (FPD) technology that provide complete procedural flexibility and Dose Tracking System (DTS) that provides real-time information on radiation dose.
“Interventional Cardiology departments are faced with increasing clinical demands, financial pressures, and the need for improved efficiency as the number and complexity of cases increase. To meet these challenges, we have introduced Alphenix / Evolve Edition” commented Kunitoshi Matsumoto, General Manager, Vascular Systems Division.
“We have rigorously tested these new AI technologies in both development and clinical phases, and are extremely confident they will have a big impact on clinical success in Interventional Cardiology. Clinical evaluation sites recently presented on their initial experiences at EuroPCR in Paris with very positive results” he continued.
*¹Alphenix / Evolve Edition and relevant functions including Echo Fusion are not commercially available in all markets and future availability cannot be guaranteed until local regulatory approvals are gained. Alphenix / Evolve Edition and Echo Fusion are not 510(k) cleared.
*² Echo Fusion accepts ultrasound images acquired by Aplio i-series (i900, i800 and i700).
Source: Canon Medical